medigraphic.com
ISSN 0035-0052 (Impreso)

2002, Número 4

<< Anterior Siguiente >>

Rev Mex Pediatr 2002; 69 (4)


Prevención y tratamiento de la desnutrición en niños con VIH

Martínez-Rojano H

Idioma: Español
Referencias bibliográficas: 72
Paginas: 155-163
Archivo PDF: 74.32 Kb.


RESUMEN

Se revisan los conocimientos que fundamentan las decisiones para la alimentación de los enfermos con VIH/SIDA; se hace mención a los aspectos particulares que deben ser considerados en los niños. En la etapa inicial, cuando aún la enfermedad no está presente, se hace especial referencia a un plan dietético individualizado, en el que figuren alimentos de todos los grupos (según el esquema con el cual se acostumbra agruparlos) para asegurar un aporte adecuado de energía, proteínas, vitaminas y minerales, procurando que éstos sean higiénicamente manejados para evitar infecciones. Una vez que se manifiesta la enfermedad, se hace énfasis en que las indicaciones dietéticas sean acordes con las limitaciones del paciente para digerir y absorber correctamente los nutrimentos. Ante tal circunstancia se recomienda el empleo de fórmulas suplementarias de alta densidad energética que aportan a su vez cantidades generosas de vitaminas y minerales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Martínez RH, Flores HLM, Torres GFE, Gutiérrez MG, Gorbea RMC. Nutritional statement and body composition of Mexican children with HIV infection In: 12th World AIDS Conference. Geneva, June 28-July 3 1998. Abstract [42364].

  2. Gorbea RMC, Martínez RH, Flores HLM, Gutiérrez MG et al. Nutritional and clinical factors associated with the progression of HIV infection in pediatric population. In: 12th World AIDS Conference. Geneva, June 28-July 3 1998. Abstract [42366].

  3. Gorbea RMC, Flores LM, Martínez RH, García GER et al. Specialized protein diet vs conventional diet for improvement of nutritional condition and immunological competence of children infected by HIV or AIDS. In: XI International Conference on AIDS. Vancouver, July 7-12, 1996. Abstract We.B.3272.

  4. Kotler DP, Tierney AR, Ferraro R et al. Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr 1991; 53(1): 149-154.

  5. Kotler DP, Tierney AR, Culpepper-Morgan JA et al. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN 1990; 14: 454-458.

  6. Lykins TC, Stockwell J. Comprehensive modified diet simplifies nutrition management of adults with short-bowel syndrome. J Am Diet Assoc 1998; 98: 309-315.

  7. Kotler DP, Fogleman L, Tierney AR. Comparison of total parenteral nutrition and an oral, semielemental diet on body composition, physical function, and nutrition-related costs in patients with malabsorption due to acquired immunodeficiency syndrome. JPEN 1998; 22: 120-126.

  8. Chlebowski RT, Beall G, Grosvenor M et al. Long-term effects of early nutritional support with new enterotropic peptide-based formula vs standard enteral formula in HIV-infected patients: randomized prospective trial. Nutrition 1993; 9(6): 507-512.

  9. Melchior JC, Chastang C, Gelas P et al. Efficacy of 2-month total parenteral nutrition in AIDS patients: a controlled randomized prospective trial. AIDS. 1996; 10(4): 379-384.

  10. Martínez-Rojano H, Gorbea RMC. Valoración del estado nutricio de niños infectados con el virus de la inmunodeficiencia humana. Rev Mex Pediatr 2001; 68(6): 264-9.

  11. Martínez-Rojano H. Manejo nutricional del paciente pediátrico infectado por el VIH/SIDA. En: Zavala TI, Gorbea RM, editores. Manejo del paciente con VIH/SIDA. México: Corporativo Intermédica, SA de CV 1999: 95-110.

  12. Gorbea-Robles MC, Flores HL, Torres GF, Fuchs VT, Martínez-Rojano H. Nutrition assessment in pediatric patients infected with the human immunodeficiency virus. Nutrition in Clinical Practice 1998; 13: 172-176.

  13. Fields-Gardner C, Thompson CA, Rhodes SS. A Clinician’s Guide to Nutrition in HIV and AIDS. Chicago: American Dietetic Association; 1997: 48-53.

  14. Nicholas S, Leung J, Fennoy I. Guidelines for nutritional support of HIV-infected children. J Pediatrics 1991; 119: 59S-62S.

  15. Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc 2000; 75: 386-394.

  16. American Dietetic Association: Position paper of the American Dietetic Association: Food fortification and dietary supplements. J Am Diet Assoc 2001; 101: 115-25.

  17. Humphrey JH, Quinn T, Fine D, Lederman H, Yamini-Roodsari et al. Short-term effects of large-dose vitamin A supplementation on viral load and immune response in HIV-infected women. J Acquir Immune Defic Sydr 1999; 20: 44-51.

  18. Baum MK, Shor-Posner G, Lu Y et al. Micronutrients and HIV-1 disease progression. AIDS 1995; 9: 1051-6.

  19. Beach RS, Morgan R, Wilkie F et al. Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency virus type 1-related cognitive changes. Arch Neurol 1992; 49(5): 501-506.

  20. Baum MK, Mantero-Atienza E, Shor-Posner G et al. Association of vitamin B6 status with parameters of immune function in early HIV-1 infection. J Acquir Immune Defic Syndr 1991; 4(11): 1122-1132.

  21. Robson LC, Schwarz RM, Perkins WD. The effects of vitamin B6 deficiency upon the lymphoid system and immune responses. In: Tryfiates CP, ed. Vitamin B6 metabolism and role in growth. Westport, Food and Nutrition Press; 1980: 205.

  22. Semba RD, Graham NMH, Caiaffa WT et al. Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection. Arch Intern Med 1993; 153(18): 2149-2154.

  23. Baum MK, Shor-Posner G, Lai S et al. High risk of HIV-related mortality is associated with selenium deficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15(5): 370-374.

  24. Allard JP, Aghdassi E, Chau J, Salit I, Walmsley S. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. Am J Clin Nutr 1998; 67(1): 143-147.

  25. Shabert JK, Winslow C, Lacey JM et al. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition 1999; 15: 860-864.

  26. Garland M, Fawzi WW. Antioxidants and progression of human immunodeficiency virus (HIV) disease. Nutr Res 1999; 19: 1259-1276.

  27. Tan AM, Graham NM, Kirby AJ. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type-1 (HIV-1) infected homosexual men. Am J Epidemiol 1993; 138: 937-951.

  28. Coodley GO, Coodley MK, Nelson HD, Loveless MO. Micronutrient concentrations in the HIV wasting syndrome. AIDS 1993; 7: 1595-1600.

  29. Noyer CM, Simon D, Borczuk A et al. A double blind, placebo-controlled pilot study of glutamine therapy for abnormal intestinal permeability in patients with AIDS. Am J Gastroenterol 1998; 93: 972-975.

  30. Shabert JK, Wilmore DW. Glutamine deficiency as a cause of human immunodeficiency virus wasting. Med Hypotheses 1996; 46: 252-256.

  31. Ziegler TR, Bendell K, Smith RJ et al. Safety and metabolic effects of L-glutamine administration in humans. J Parenter Enteral Nutr 1990; 14(suppl 4): 137S-146S.

  32. Mantero-Atienza E, Baum MK, Javier JJ, Shor-Posner G et al. Nutritional knowledge, beliefs and practices in the HIV infected patient. Nutr Res 1991; 2: 33-40.

  33. Ward BJ, Humphrey JH, Clement H, Chaisson RE. Vitamin A status in HIV infection. Nutr Res 1993; 13: 157-166.

  34. Abrams B, Duncan D, Hertz-Picciotto I. A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men. J Acquir Immune Defic Syndr 1993; 6: 949-958.

  35. Macallan DC, Noble C, Baldwin C, Foskett M et al. Prospective analysis of patterns of weight change in state IV human immunodeficiency virus infection. Am J Clin Nutr 1993; 58: 417-424.

  36. Thurnham DI. Vitamin A deficiency and its role in infection. Trans Roy Soc Trop Med Hyg 1989; 83: 721-723.

  37. Hellerstein MK, Wu K, McGrath M et al. Effects of dietary omega-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: relation to indices of cytokine production. J Acquir Immune Defic Syndr 1996; 11: 258-270.

  38. Segal DM, Perez M, Shapshak P. Oxandrolone, used for treatment of wasting disease in HIV-1-infected patients, does not diminish the antiviral activity of deoxynucleoside analogues in lymphocyte and macrophage cell cultures. J Acquir Immune Defic Syndr 1999; 20: 215-219.

  39. Strawford A, Barbieri T, Neese R, Van Loan M, Christiansen M et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr 1999; 20: 137-146.

  40. Paton NI, Newton PJ, Sharpstone DR et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS 1999; 13: 1195-1202.

  41. Fox-Wheeler S, Heller L, Salata CM et al. Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients. Pediatrics 1999; 104: 1-7.

  42. Von Roenn JH, Armstrong D, Kotler D et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994; 121(6): 393-399.

  43. Oster MH, Enders SP, Samuels SJ et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994; 121(6): 400-408.

  44. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 77(4): 956-962.

  45. Bhasin S, Storer TW, Berman N et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335(1): 1-7.

  46. Gold J, High HA, Li Y et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996; 10(7): 745-752.

  47. Thea DM, Porat R, Nagimbi K et al. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1. Ann Intern Med 1996; 124(8): 757-762.

  48. Engelson ES, Pi-Sunyer FX, Kotler DP. Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS. AIDS 1995; 9: 1107-1108.

  49. Mann M, Koller E, Murgo A et al. Glucocorticoid-like activity of megestrol. Arch Intern Med 1997; 157: 1651-1656.

  50. Beal JE, Olson R, Laubenstein L et al. Dronabinol as a treatment for anorexia associated weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89-97.

  51. Dobs AS. Is there a role for androgenic anabolic steroids in medical practice? JAMA 1999; 281: 1326-1327.

  52. Grinspoon S, Corcoran C, Askari H et al. Effects of androgen administration in men with the AIDS wasting syndrome. Ann Intern Med 1998; 129: 18-26.

  53. Grinspoon S, Corcoran C, Lee K et al. Loss of lean body mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 1996; 81: 4051-4058.

  54. Hengge UR, Baumann M, Maleba R et al. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 1996; 75: 129-138.

  55. Fisher A, Abbatilola M. The effects of oxandrolone on body weight and composition in patients with HIV-associated weight loss. In: Program and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva. Abstract 42351.

  56. Strawford A, Barbieri T, Van Loan M et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV related weight loss. JAMA 1999; 281: 1282-1290.

  57. Miller K, Corcoran C, Armstrong C et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 1998; 83: 2717-2725.

  58. Torres RA, Unger KW, Cadman JA, Kassous JY. Recombinant human growth hormone improves truncal adiposity and ‘buffalo humps’ in HIV-positive patients on HAART. AIDS 1999; 13(17): 2479-2481.

  59. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999; 13(15): 2099-2103.

  60. Engelhard P, Strawbridge T. The use of growth hormone (Serostim) in patients with HIV-associated adipose redistribution syndrome (HARS). Program and abstracts of the XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract TuPeB3151.

  61. Corcoran C, Grinspoon S, Anderson E et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. Program and abstracts of the XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract WePpB1383.

  62. Spence DW, Galantino MLA, Mossberg KA et al. Progressive resistance exercise: effect on muscle function and anthropometry of a select AIDS population. Arch Phys Med Rehabil 1990; 71: 644-648.

  63. Rigsby LW, Dishman RK, Jackson AW et al. Effects of exercise training on men seropositive for the human immunodeficiency virus-1. Med Sci Sports Exerc. References.

  64. Johnson JE, Anders GT, Blanton HM et al. Exercise dysfunction in patients seropositive for the human immunodeficiency virus. Am Rev Resp Dis 1990; 141: 618-22.

  65. Ullum H, Palmo J, Harkjaer-Kristensen J et al. The effect of acute exercise on lymphocyte subsets, natural killer cells, proliferative responses, and cytokines in HIV-seropositive persons. J Acquir Immune Defic Syndr Hum Retrovirol 1994; 7: 1122-33.

  66. MacArthur RD, Levine SID, Birk TJ. Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Med Sci Sports Exerc 1993; 25: 684-88.

  67. Jaquet D, Lévine M, Ortega-Rodriguez E, Faye A et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14: 2123-8.

  68. Center for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV-infection. MMWR 1998; 47(RR-4): 1-44.

  69. Regan AM, Babl FE. Abnormal body fat accumulations in HIV infected children on antiretroviral therapy. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998 [abstract 1-86].

  70. Watson DC, Farley JJ. Hypercholesterolemia in children treated with HIV protease inhibitors. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999; [Abstract A435].

  71. Rivera S, Briggs W, Qian D et al. Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 411-418.

  72. Kotler DP. Management of nutritional alterations and issues concerning quality of life. J Acquir Immune Defic Syndr 1997; 16(Suppl. 1): S30-S35.




2020     |     www.medigraphic.com